Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients

Pasquier, David; Barney, Bradley J.; Sundar, Santhanam; Poortmans, Philip; Villà, Salvador; Nasrallah, Haitam; Boujelbene, N.; Ghadjar, Pirus; Lassen‐Ramshad, Yasmin; Senkus, Elżbieta; Oar, Andrew; Roelandts, Martine; Amichetti, Maurizio; Vees, Hansjoerg; Zilli, Thomas; Ozşahin, Mahmut

doi:10.1016/j.ijrobp.2015.03.019

Cited by 54 publications

(47 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study revealed several important findings. First, although the association between histological subtype and prognosis of BC has been investigated before, previous population-based studies were limited only to one rare histological subtype of BC such as SQCC [7–9], AD [18, 19] or SCC [4, 5, 20–24], or had relatively small sample sizes [6]. SQCC histology was reported to be an independent predictor of higher all-cause and bladder cancer-specific mortality as compared to TCC among patients with advanced stages (AJCC stage III/IV) [7].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic value of histological subtype in patients with metastatic bladder cancer

Chen

et al. 2017

Oncotarget

View full text Add to dashboard Cite

We aim to evaluate the prognostic effect of the histological sub-type in patients with metastatic bladder cancer based on the Surveillance Epidemiology and End Results database. A total of 2634 eligible patients were included. The histological subtypes were: transitional cell carcinoma (TCC; 75.2%); adenocarcinoma (3.3%); squamous cell carcinoma (SQCC; 4.1%); and small cell carcinoma (4.3%). A significant association of adenocarcinoma with better survival outcomes (P < 0.015), and that of SQCC with worse outcomes (P < 0.001) was observed. On multivariate analysis, adenocarcinoma was significantly associated with longer and SQCC with shorter survival time as compared to TCC. Overall, 1331 (50.5%) patients had a single metastatic site and 523 (19.9%) had multiple sites involved. Single-site metastasis had a better survival outcome than multiple metastases (P < 0.001). Histological sub-type and presence of multiple metastatic sites are independent predictors of survival time. Prospective, in-depth research is needed to determine optimal therapeutic strategies for different histological subtypes of bladder cancer with different metastatic patterns.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Other histological subtypes include squamous cell carcinoma (SQCC), adenocarcinoma (AD), small cell carcinoma (SCC) and some other rare non-epithelial subtypes. Among these, SQCC, AD and SCC account for less than 5%, 2% [3] and 1% [4, 5] of all primary bladder tumors, respectively.…”

Section: Introductionmentioning

confidence: 99%

The prognostic value of histological subtype in patients with metastatic bladder cancer

Chen

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…So far, a standard treatment strategy for SCC of the urinary bladder has not yet been established. Recently, the efficacy of adjuvant or neo-adjuvant chemotherapy similar to chemotherapy regimens for SCC of lung cancer, together with radical cystectomy or radiation, has been reported [8, 9, 10]. This indicates that an accurate diagnosis of SCC of the urinary bladder is related to better prognosis.…”

Section: Discussionmentioning

confidence: 99%

Transdifferentiation of Small Cell Carcinoma of the Urinary Bladder from Urothelial Carcinoma after Transurethral Resection of a Bladder Tumor, Intravesical Bacillus Calmette-Guerin Instillation, and Chemotherapy: A Case Report

et al. 2016

View full text Add to dashboard Cite

A 73-year-old male underwent transurethral resection of a bladder tumor in August 2010 and April 2011. Pathological examination revealed urothelial carcinoma. After the surgery, chemotherapy and intravesical Bacillus Calmette-Guerin instillation were performed. In September 2014, he once again underwent transurethral resection of the bladder tumor for recurrence, and was again diagnosed with urothelial carcinoma, pT2, by pathological examination. After neoadjuvant chemotherapy, radical cystectomy for tumor recurrence was performed. Pathological examination at this time revealed small cell carcinoma, pT3N0. It is rare for urothelial carcinoma to change to small cell carcinoma, and the mechanism and cause of this change are still unknown. In this case report, we discuss what causes small cell carcinoma of the urinary bladder and review the literature regarding its origin.

show abstract

“…Both are very aggressive tumors, characterized by rapid progression with high metastatic potential. Patients with NE carcinoma have worse outcomes compared with conventional urothelial carcinoma, with median survival ranging between 9 to 20 months after curative intent in the nonmetastatic setting (2,3,(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Molecular Characterization of Neuroendocrine-like Bladder Cancer

Costa

Gibb²,

Bivalacqua³

et al. 2019

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Neuroendocrine (NE) bladder carcinoma is a rare and aggressive variant. Molecular subtyping studies have found that 5% to 15% of muscle-invasive bladder cancer (MIBC) have transcriptomic patterns consistent with NE bladder cancer in the absence of NE histology. The clinical implications of this NE-like subtype have not been explored in depth.Experimental Design: Transcriptome-wide expression profiles were generated for MIBC collected from 7 institutions and clinical-use of Decipher Bladder. Using unsupervised clustering, we generated a clustering solution on a prospective training cohort (PTC; n ¼ 175), developed single-sample classifiers to predict NE tumors, and evaluated the resultant models on a testing radical cystectomy (RC) cohort (n ¼ 225). A random forest model was finalized and applied to 5 validation cohorts (n ¼ 1302). Uni-and multivariable survival analyses were used to characterize clinical outcomes. Results:In the training cohort (PTC), hierarchical clustering using an 84-gene panel showed a cluster of 8 patients (4.6%) with highly heterogeneous expression of NE markers in the absence of basal or luminal marker expression. NE-like tumors were identified in 1% to 6.6% of cases in validation cohorts. Patients with NE-like tumors had significantly worse 1-year progression-free survival (65% NE-like vs. 82% overall; P ¼ 0.046) and, after adjusting for clinical and pathologic factors, had a 6.4-fold increased risk of all-cause mortality (P ¼ 0.001). IHC confirmed the neuronal character of these tumors.Conclusions: A single-patient classifier was developed that identifies patients with histologic urothelial cancer harboring a NE transcriptomic profile. These tumors represent a high-risk subgroup of MIBC, which may require different treatment. a P <0.05.Batista da Costa et al.

show abstract

Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients

Cited by 54 publications

References 19 publications

The prognostic value of histological subtype in patients with metastatic bladder cancer

The prognostic value of histological subtype in patients with metastatic bladder cancer

Transdifferentiation of Small Cell Carcinoma of the Urinary Bladder from Urothelial Carcinoma after Transurethral Resection of a Bladder Tumor, Intravesical Bacillus Calmette-Guerin Instillation, and Chemotherapy: A Case Report

Molecular Characterization of Neuroendocrine-like Bladder Cancer

Contact Info

Product

Resources

About